Efficacy of Mass Vaccination with Pfizer/BioNTech against COVID-19 in Israel

We need to know how effective vaccines are by population subgroup outside the controlled setting of a clinical trial. 

Eficacia del uso masivo de la vacuna de Pfizer/BioNTech contra el COVID-19 en Israel

Israel was one of the first countries to deploy a nationwide mass vaccination strategy. This is why it results ideal to compare its results against clinical trial results. 

All subjects receiving the BNT162b2 mRNA Covid-19 Vaccine (Pfizer/BioNTech) between December 20, 2020 and February 1, 2021, were compared 1:1 against unvaccinated control subjects according to demographic and clinical characteristics. 

Primary end point was documented symptomatic COVID-19 infection, hospitalization, severe disease, and death.  

Each study group included more than a million people (596618 individuals). Vaccine effectiveness was estimated between 14 and 20 days after the first dose and 7 or more days after the second dose. 

For documented infection, efficacy was 46% after the first dose. It climbed to 92% one week after the second dose. For symptomatic disease, efficacy was 57 and 94% for the first and second doses respectively, and hospitalization for COVID 19 infection was 74 an 87%. 


Read also: High Deployment: Also Trending with Balloon Expandable Valves.


Effectiveness in preventing death was estimated only after receiving the first dose, and was 72%.

These outcomes were consistent across age groups, with potentially slightly lower effectiveness in persons with multiple risk factors.

Conclusion

This study in a nationwide mass vaccination setting in Israel suggests that the BNT162b2 mRNA vaccine (Pfizer/BioNTech) is effective for all end points, in addition to being consistent with data obtained through randomized studies.

nejmoa2101765

Original Title: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Reference: Noa Dagan et al. N Engl J Med. 2021 Feb 24. Online ahead of print. doi: 10.1056/NEJMoa2101765. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who...

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...